Treatment options in Alzheimer's disease: Maximizing benefit, managing expectations

Martin Farlow, Michael L. Miller, Vojislav Pejovic

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is becoming an increasingly heavy burden on the society of developed countries, and physicians now face the challenge of providing efficient treatment regimens to an ever-higher number of individuals affected by the disease. Currently approved anti-AD therapies - the cholinesterase inhibitors and the N-methyl-D-aspartate receptor antagonist memantine - offer modest symptomatic relief, which can be enhanced using combination therapy with both classes of drugs. Additionally, alternative therapies such as nonsteroidal anti-inflammatory drugs, vitamin E, selegiline, Ginkgo biloba extracts, estrogens, and statins, as well as behavioral and lifestyle changes, have been explored as therapeutic options. Until a therapy is developed that can prevent or reverse the disease, the optimal goal for effective AD management is to develop a treatment regimen that will yield maximum benefits for individual patients across multiple domains, including cognition, daily functioning, and behavior, and to provide realistic expectations for patients and caregivers throughout the course of the disease. This review provides a basic overview of approved AD therapies, discusses some pharmacologic and nonpharmacologic treatment strategies that are currently being investigated, and offers suggestions for optimizing treatment to fit the needs of individual patients.

Original languageEnglish
Pages (from-to)408-422
Number of pages15
JournalDementia and Geriatric Cognitive Disorders
Volume25
Issue number5
DOIs
StatePublished - Apr 2008

Fingerprint

Alzheimer Disease
Therapeutics
Memantine
Selegiline
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Ginkgo biloba
Cholinesterase Inhibitors
Complementary Therapies
Disease Management
N-Methyl-D-Aspartate Receptors
Vitamin E
Developed Countries
Pharmaceutical Preparations
Cognition
Caregivers
Life Style
Estrogens
Anti-Inflammatory Agents
Physicians

Keywords

  • Alzheimer's disease
  • Antioxidants
  • Cholinesterase inhibitors
  • Combination therapy
  • Ginkgo biloba
  • Memantine
  • Pharmacotherapy

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Geriatrics and Gerontology

Cite this

Treatment options in Alzheimer's disease : Maximizing benefit, managing expectations. / Farlow, Martin; Miller, Michael L.; Pejovic, Vojislav.

In: Dementia and Geriatric Cognitive Disorders, Vol. 25, No. 5, 04.2008, p. 408-422.

Research output: Contribution to journalArticle

@article{7261ea67b5324b95b45b7b533d3379e3,
title = "Treatment options in Alzheimer's disease: Maximizing benefit, managing expectations",
abstract = "Alzheimer's disease (AD) is becoming an increasingly heavy burden on the society of developed countries, and physicians now face the challenge of providing efficient treatment regimens to an ever-higher number of individuals affected by the disease. Currently approved anti-AD therapies - the cholinesterase inhibitors and the N-methyl-D-aspartate receptor antagonist memantine - offer modest symptomatic relief, which can be enhanced using combination therapy with both classes of drugs. Additionally, alternative therapies such as nonsteroidal anti-inflammatory drugs, vitamin E, selegiline, Ginkgo biloba extracts, estrogens, and statins, as well as behavioral and lifestyle changes, have been explored as therapeutic options. Until a therapy is developed that can prevent or reverse the disease, the optimal goal for effective AD management is to develop a treatment regimen that will yield maximum benefits for individual patients across multiple domains, including cognition, daily functioning, and behavior, and to provide realistic expectations for patients and caregivers throughout the course of the disease. This review provides a basic overview of approved AD therapies, discusses some pharmacologic and nonpharmacologic treatment strategies that are currently being investigated, and offers suggestions for optimizing treatment to fit the needs of individual patients.",
keywords = "Alzheimer's disease, Antioxidants, Cholinesterase inhibitors, Combination therapy, Ginkgo biloba, Memantine, Pharmacotherapy",
author = "Martin Farlow and Miller, {Michael L.} and Vojislav Pejovic",
year = "2008",
month = "4",
doi = "10.1159/000122962",
language = "English",
volume = "25",
pages = "408--422",
journal = "Dementia and Geriatric Cognitive Disorders",
issn = "1420-8008",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - Treatment options in Alzheimer's disease

T2 - Maximizing benefit, managing expectations

AU - Farlow, Martin

AU - Miller, Michael L.

AU - Pejovic, Vojislav

PY - 2008/4

Y1 - 2008/4

N2 - Alzheimer's disease (AD) is becoming an increasingly heavy burden on the society of developed countries, and physicians now face the challenge of providing efficient treatment regimens to an ever-higher number of individuals affected by the disease. Currently approved anti-AD therapies - the cholinesterase inhibitors and the N-methyl-D-aspartate receptor antagonist memantine - offer modest symptomatic relief, which can be enhanced using combination therapy with both classes of drugs. Additionally, alternative therapies such as nonsteroidal anti-inflammatory drugs, vitamin E, selegiline, Ginkgo biloba extracts, estrogens, and statins, as well as behavioral and lifestyle changes, have been explored as therapeutic options. Until a therapy is developed that can prevent or reverse the disease, the optimal goal for effective AD management is to develop a treatment regimen that will yield maximum benefits for individual patients across multiple domains, including cognition, daily functioning, and behavior, and to provide realistic expectations for patients and caregivers throughout the course of the disease. This review provides a basic overview of approved AD therapies, discusses some pharmacologic and nonpharmacologic treatment strategies that are currently being investigated, and offers suggestions for optimizing treatment to fit the needs of individual patients.

AB - Alzheimer's disease (AD) is becoming an increasingly heavy burden on the society of developed countries, and physicians now face the challenge of providing efficient treatment regimens to an ever-higher number of individuals affected by the disease. Currently approved anti-AD therapies - the cholinesterase inhibitors and the N-methyl-D-aspartate receptor antagonist memantine - offer modest symptomatic relief, which can be enhanced using combination therapy with both classes of drugs. Additionally, alternative therapies such as nonsteroidal anti-inflammatory drugs, vitamin E, selegiline, Ginkgo biloba extracts, estrogens, and statins, as well as behavioral and lifestyle changes, have been explored as therapeutic options. Until a therapy is developed that can prevent or reverse the disease, the optimal goal for effective AD management is to develop a treatment regimen that will yield maximum benefits for individual patients across multiple domains, including cognition, daily functioning, and behavior, and to provide realistic expectations for patients and caregivers throughout the course of the disease. This review provides a basic overview of approved AD therapies, discusses some pharmacologic and nonpharmacologic treatment strategies that are currently being investigated, and offers suggestions for optimizing treatment to fit the needs of individual patients.

KW - Alzheimer's disease

KW - Antioxidants

KW - Cholinesterase inhibitors

KW - Combination therapy

KW - Ginkgo biloba

KW - Memantine

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=43049129669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049129669&partnerID=8YFLogxK

U2 - 10.1159/000122962

DO - 10.1159/000122962

M3 - Article

C2 - 18391487

AN - SCOPUS:43049129669

VL - 25

SP - 408

EP - 422

JO - Dementia and Geriatric Cognitive Disorders

JF - Dementia and Geriatric Cognitive Disorders

SN - 1420-8008

IS - 5

ER -